Sphera Funds Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Sphera Funds Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-213,625	Closed	-$5.52M	–	137
2018 Q2	$5.52M	Sell	213,625 -121,875	-36%	-$3.37M	0.76%	35
2018 Q1	$8.02M	Buy	335,500 +195,000	+139%	+$6.15M	1.22%	20
2017 Q4	$4.76M	Buy	140,500 +25,000	+22%	+$698K	0.56%	42
2017 Q3	$2.44M	Sell	115,500 -80,000	-41%	-$1.47M	0.35%	75
2017 Q2	$3.42M	Hold	195,500	–	–	0.58%	53
2017 Q1	$3.42M	Sell	195,500 -74,500	-28%	-$1.27M	0.67%	42
2016 Q4	$4.56M	Hold	270,000	–	–	1.16%	21
2016 Q3	$4.43M	Hold	270,000	–	–	0.72%	31
2016 Q2	$4.09M	Hold	270,000	–	–	1.06%	26
2016 Q1	$3.9M	Buy	270,000 +120,000	+80%	+$2.02M	0.85%	21
2015 Q4	$4.25M	Buy	+150,000	New	+$2.53M	0.62%	31

Other funds holding ADMS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Sphera Funds Management's ADMS Position: Q3 2018 in Review

Sphera Funds Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 213,625 shares — an estimated $5.52M sold.

Sphera Funds Management first reported a position in ADMS in Q4 2015 and held it in 11 quarters. The position peaked at $8.02M in Q1 2018. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

Sphera Funds Management reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Sphera Funds Management sold 213,625 Adamas Pharmaceuticals shares in Q3 2018, an estimated $5.52M.
Sphera Funds Management first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 11 quarters.
Sphera Funds Management's Adamas Pharmaceuticals position peaked at $8.02M in Q1 2018.
125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on Sphera Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.